Prelude Therapeutics Incorporated PRLD
$ 1.18
32.32%
Quarterly report 2024-Q3
added 11-06-2024
Country |
USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
CEO |
Dr. Krishna Vaddi D.V.M., Ph.D. |
Employees in the company |
55 |
Shares |
60.4 M |
Market Cap[1] |
$ 71.2 M |
EBITDA (LTM) |
$ -121 M |
P/E (LTM) |
-0.76 |
P/S (LTM) |
26.76 |
EPS (LTM) |
-1.76 |
Other stocks of industry "Biotechnology"
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.